Herantis Pharma Oyj reported consolidated earnings results for the year ended December 31, 2015. For the year, the company reported net turnover of EUR 1,955.00 against EUR 800.00 a year ago. Operating loss was EUR 16,166,253.34 against EUR 7,656,641.77 a year ago. Loss before extraordinary items was EUR 16,044,683.39 against EUR 8,356,443.49 a year ago. Loss before appropriations and taxes was EUR 16,044,683.39 against EUR 8,356,443.49 a year ago. Consolidated loss was EUR 16,044,483.39 against EUR 8,356,443.49 a year ago. Cash flow used in operating activities was EUR 7,397,714.90 against EUR 4,346,365.29 a year ago. Capital expenditure on other investments was EUR 0.00 against EUR 1,162.50 a year ago. Loss per share was EUR 3.94 compared with EUR 3.21 a year ago.

For the year 2016. The company expects the financial position is expected to be positive at the end of the period.